Nonalcoholic steatohepatitis: An emerging cause of cirrhosis in Colombia

Authors

DOI:

https://doi.org/10.22516/25007440.783

Keywords:

Nonalcoholic fatty liver disease, cirrhosis of the liver, Metabolic syndrome

Abstract

Introduction: Cirrhosis of the liver is a significant cause of morbidity and mortality in Latin America; the increased prevalence of metabolic syndrome in our population could be changing the epidemiological profile of patients with advanced chronic liver disease.

Aim: To characterize a group of patients with cirrhosis of the liver at an outpatient hepatology care center in Cartagena de Indias, Colombia, and determine the contribution of nonalcoholic steatohepatitis (NASH) as an etiological factor in this population.

Materials and methods: Retrospective, cross-sectional, analytical study. All patients who attended the hepatology follow-up with a diagnosis of cirrhosis of the liver were in the six-monthly follow-up protocol that included screening for hepatocellular carcinoma (HCC) and esophageal varices.

Results: 346 patients were included, most were women (54.3 %). The first and second causes of cirrhosis were cryptogenic (35 %) and NASH (30.9 %), respectively, followed by viral hepatitis (17 %) and autoimmune diseases (9 %). Of these patients, 87.4 % were within categories A and B of the Child-Turcotte-Pugh score, and only 12.5 % (33 patients) were in stage C. Also, 60 % had at least one clinical decompensation, 38 % a history of variceal hemorrhage, and 4 % a diagnosis of HCC; 80.6 % of patients with NASH cirrhosis had diabetes, and 46.7 % were overweight.

Conclusion: NASH cirrhosis is an emerging cause of advanced chronic liver disease in Colombia.

Downloads

Download data is not yet available.

Author Biographies

Juan David Vélez Aguirre, Universidad de Cartagena

Médico y cirujano. Residente de Medicina Interna. PHAROS, grupo de investigación en Ciencia,
Tecnología y Salud, Cartagena, Colombia.

Lourdes Helene Lepesqueur Guillén, Gastropack SAS

Médico general. Grupo de investigación Gastropack. Soluciones integrales en Gastroenterología y Hepatología
SAS. Cartagena de Indias. Colombia.

 

Ismael de Jesús Yepes Barreto, Gastropack SAS

Hepatólogo y gastroenterólogo. PHAROS, grupo de investigación en Ciencia, Tecnología y Salud, Grupo de investigación Gastropack. Soluciones integrales en Gastroenterología y Hepatología SAS. Universidad de Cartagena. Cartagena, Colombia.

References

D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217-31. https://doi.org/10.1016/j.jhep.2005.10.013

Balabaud C, Bioulac-Sage P. Cirrhosis: what else? Gastroenterol Clin Biol. 2010;34(4-5):252-4. https://doi.org/10.1016/j.gcb.2010.03.007

Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician. 2006;74(5):756-62.

Laclé-Murray A, Esquivel-Chaverri M, Madrigal-López M, Alpízar-Chacón C. Prevalencia de esteatosis hepática no alcohólica en personas diabéticas tipo 2. Acta Médica Costarricense. 2014;56(1):17-22. https://doi.org/10.51481/amc.v56i1.826

Souza MR, Diniz Mde F, Medeiros-Filho JE, Araújo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol. 2012;49(1):89-96. https://doi.org/10.1590/s0004-28032012000100015

Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11-20. https://doi.org/10.1038/nrgastro.2017.109

Nassir F, Rector RS, Hammoud GM, Ibdah JA. Pathogenesis and Prevention of Hepatic Steatosis. Gastroenterol Hepatol (N Y). 2015;11(3):167-75.

Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic Steatohepatitis: A Review. JAMA. 2020;323(12):1175-1183. https://doi.org/10.1001/jama.2020.2298

Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51(6):1972-8. https://doi.org/10.1002/hep.23527

Giraldo Montoya ÁM, Barraza Amador M, Villa Velásquez H, Martínez JW, García Castro G. Caracterización epidemiológica de pacientes con cirrosis en una consulta de gastroenterología en Pereira, Colombia, 2009-2012. Revista Médica Risaralda. 2014;20(2):86-94.

Escorcia, E Marrugo W. Caracterización epidemiológica y clínica de la cirrosis hepática en un centro regional del caribe colombiano: clínica general del norte. Enero 2012 a marzo 2017. Biociencias. 2018;13(1):17-30. https://doi.org/10.18041/2390-0512/bioc..1.2242

Prieto JE, Sánchez PS, Prieto RG, Rojas EL, González L, Mendivelso F. Características clínicas y descompensación en pacientes con cirrosis hepática atendidos en dos centros de hepatología en la ciudad de Bogotá D.C., 2010-2014. Rev Colomb Gastroenterol. 2016;31(1):1-8. https://doi.org/10.22516/25007440.66

de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743-52. https://doi.org/10.1016/j.jhep.2015.05.022

Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723-750. https://doi.org/10.1002/hep.29913

Calès P, Zabotto B, Meskens C, Caucanas JP, Vinel JP, Desmorat H, et al. Gastroesophageal endoscopic features in cirrhosis. Observer variability, interassociations, and relationship to hepatic dysfunction. Gastroenterology. 1990;98(1):156-62. https://doi.org/10.1016/0016-5085(90)91305-P

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. https://doi.org/10.1002/hep.29367

Ghany MG, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71(2):686-721. https://doi.org/10.1002/hep.31060

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. https://doi.org/10.1002/hep.29800

Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020;72(2):671-722. https://doi.org/10.1002/hep.31065

Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology. 2020;71(1):306-333. https://doi.org/10.1002/hep.30866

Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394-419. https://doi.org/10.1002/hep.30145

Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51(2):660-78. https://doi.org/10.1002/hep.23294

Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11(1):74-80. https://doi.org/10.1002/hep.1840110114

Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL, et al. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol. 2002;33(11):1098-104. https://doi.org/10.1053/hupa.2002.129419

Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl. 2001;7(4):363-73. https://doi.org/10.1053/jlts.2001.23011

Caldwell SH, Lee VD, Kleiner DE, Al-Osaimi AM, Argo CK, Northup PG, et al. NASH and cryptogenic cirrhosis: a histological analysis. Ann Hepatol. 2009;8(4):346-52. https://doi.org/10.1016/S1665-2681(19)31748-X

Li B, Zhang C, Zhan YT. Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. Can J Gastroenterol Hepatol. 2018;2018:2784537. https://doi.org/10.1155/2018/2784537

Kabbany MN, Conjeevaram Selvakumar PK, Watt K, Lopez R, Akras Z, Zein N, et al. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. Am J Gastroenterol. 2017;112(4):581-587. https://doi.org/10.1038/ajg.2017.5

Abarca J, Peñaherrera V, Garcés C, Córdova A, Carrillo L, Sáenz R. Etiología, sobrevida, complicaciones y mortalidad en cirrosis hepática en el Ecuador. Evaluación retrospectiva de 15 años (1989-2003). Gastr Latinoam. 2006;17(1):29-34.

García DS, Martínez Artola Y, Poncino DA, Ferreira Rubino M, Escobar R, Khoury M. Etiología de la cirrosis: los cambios epidemiológicos entre los períodos 1995-2002 y 2010-2017. Acta Gastroenterol Latinoam. 2020;50(3):271-8. https://doi.org/10.52787/JEFK3470

Encuesta Nacional de la Situación Nutricional (ENSIN 2015) [Internet]. OSAN Colombia - Observatorio de Seguridad Alimentaria y Nutrición. Ministerio de Salud de la República de Colombia. [citado el 20 de noviembre de 2021]. Disponible en línea: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/PSP/presentacion-lanzamiento-ensin-2015.pdf

Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med. 2016;26(4):364-73. https://doi.org/10.1016/j.tcm.2015.10.004

Lima ML, Mourão SC, Diniz MT, Leite VH. Hepatic histopathology of patients with morbid obesity submitted to gastric bypass. Obes Surg. 2005;15(5):661-9. https://doi.org/10.1381/0960892053923888

Boza C, Riquelme A, Ibañez L, Duarte I, Norero E, Viviani P, Soza A, Fernandez JI, Raddatz A, Guzman S, Arrese M. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg. 2005;15(8):1148-53. https://doi.org/10.1381/0960892055002347

D’Amico G, Perricone G. Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter? Curr Hepatol Reports. 2019;18(2):144-56. https://doi.org/10.1007/s11901-019-00473-1

Figura 1. Distribución de etiologías de la cirrosis

Published

2022-05-31

How to Cite

Vélez Aguirre, J. D., Lepesqueur Guillén, L. H., & Yepes Barreto, I. de J. (2022). Nonalcoholic steatohepatitis: An emerging cause of cirrhosis in Colombia. Revista Colombiana De Gastroenterología, 37(2), 136–144. https://doi.org/10.22516/25007440.783

Issue

Section

Originals articles

Altmetric

Crossref Cited-by logo
Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
QR Code

Some similar items: